Journey Medical Corporati... (DERM)
| Bid | 5.82 |
| Market Cap | 143.36M |
| Revenue (ttm) | 56.13M |
| Net Income (ttm) | -14.67M |
| EPS (ttm) | -0.72 |
| PE Ratio (ttm) | -8.62 |
| Forward PE | -67.67 |
| Analyst | Buy |
| Ask | 7.22 |
| Volume | 45,545 |
| Avg. Volume (20D) | 69,414 |
| Open | 6.00 |
| Previous Close | 6.03 |
| Day's Range | 6.04 - 6.30 |
| 52-Week Range | 3.20 - 7.29 |
| Beta | 0.91 |
About DERM
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; X...
Analyst Forecast
According to 2 analyst ratings, the average rating for DERM stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 61.16% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Journey Medical Corporation (DERM) Q4 2024 Earnings Call TranscriptJourney Medical Corporation (NASDAQ:DERM ) Q4 2024 Results Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Found...
2 months ago · seekingalpha.com
Journey Medical Corporation: Emrosi's Launch Could Be A Turning PointJourney Medical's future hinges on Emrosi™, a new formulation of minocycline for rosacea, showing superior efficacy over Oracea® in Phase III trials. Despite current financial challenges and a need fo...